NVP-BEZ235 Induces Tumor Regression in Colorectal Cancer
Author Information
Author(s): Jatin Roper, Michael P. Richardson, Wei Vivian Wang, Larissa Georgeon, Wei Chen, Erin M. Coffee, Mark J. Sinnamon, Lydia Lee, Peng-Chieh Chen, Roderick T. Bronson, Eric S. Martin, Kenneth E. Hung
Primary Institution: Tufts Medical Center
Hypothesis
NVP-BEZ235 may have significant efficacy in the treatment of PIK3CA wild-type colorectal cancer.
Conclusion
NVP-BEZ235 treatment results in significant regression of PIK3CA wild-type colonic tumors.
Supporting Evidence
- In vitro treatment of CRC cell lines with NVP-BEZ235 resulted in decreased cell viability.
- In vivo treatment of colonic tumor-bearing mice with NVP-BEZ235 resulted in a 43% decrease in tumor size.
- Longitudinal tumor surveillance showed a significant difference in tumor growth between control and treated groups.
Takeaway
This study shows that a drug called NVP-BEZ235 can help shrink tumors in mice with a type of colon cancer that doesn't have a specific mutation.
Methodology
The study involved in vitro and in vivo experiments using human colorectal cancer cell lines and a genetically engineered mouse model.
Statistical Information
P-Value
p=0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website